The Texas Office of the Attorney General’s (OAG) Civil Medicaid Fraud Division filed a lawsuit against several major pharmaceutical manufacturers including Pfizer, Tris Pharma, and Tris Pharma CEO Ketan Mehta, alleging violations of the Texas Health Care Program Fraud Prevention Act (THFPA).
According to the OAG, the defendant companies sold a medication intended to treat attention deficit hyperactivity disorder in children called Quillivant. The office contends the drug failed quality-control tests and was subject to a flawed manufacturing process.
The OAG also alleges the defendants illegally altered the drug testing procedures against regulatory standards and knowingly continued to sell the drug for years.
The suit alleges that the defendants violated the THFPA in misrepresenting or concealing their failure to comply with manufacturing standards from decision-makers with the Texas Medicaid Program, in order to ensure the drugs would qualify for and be approved for reimbursement through Medicaid funding.
Source: Pfizer, Tris Pharma Sued by Texas Attorney General for Medicaid Fraud / The Texan